巨噬细胞与冠心病的相关性研究进展

doi:10.3969/j.issn.1003-9198.2021.12.003

[1] 《中国心血管健康与疾病报告2020》编写组.《中国心血管健康与疾病报告2020》概述[J]. 中国心血管病研究,2021,19(7):582-590.
[2] HE X, MATAM B R, BELLARY S, et al. CHD risk minimization through lifestyle control: machine learning gateway [J]. Sci Rep, 2020, 10(1): 4090.
[3] PARK I, KASSITERIDI C, MONACO C. Functional diversity of macrophages in vascular biology and disease [J]. Vascul Pharmacol, 2017, 99: 13-22.
[4] XU H, JIANG J, CHEN W, et al. Vascular macrophages in atherosclerosis [J]. J Immunol Res, 2019, 2019: 4354786.
[5] MOORE K J, SHEEDY F J, FISHER E A. Macrophages in atherosclerosis: a dynamic balance [J]. Nat Rev Immunol, 2013, 13(10): 709-721.
[6] GROH L, KEATING S T, JOOSTEN L A B, et al. Monocyte and macrophage immunometabolism in atherosclerosis [J]. Semin Immunopathol, 2018, 40(2): 203-214.
[7] BORING L, GOSLING J, CLEARY M, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis [J]. Nature, 1998, 394(6696): 894-897.
[8] YANG S, YUAN H Q, HAO Y M, et al. Macrophage polarization in atherosclerosis [J]. Clin Chim Acta, 2020, 501: 142-146.
[9] MESTAS J, LEY K. Monocyte-endothelial cell interactions in the development of atherosclerosis [J]. Trends Cardiovasc Med, 2008, 18(6): 228-232.
[10] LUO W, WANG H, OHMAN M K, et al. P-selectin glycoprotein ligand-1 deficiency leads to cytokine resistance and protection against atherosclerosis in apolipoprotein E deficient mice [J]. Atherosclerosis, 2012, 220(1): 110-117.
[11] SWIRSKI F K, NAHRENDORF M, ETZRODT M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites [J]. Science, 2009, 325(5940): 612-616.
[12] ADAMSON S, LEITINGER N. Phenotypic modulation of macrophages in response to plaque lipids [J]. Curr Opin Lipidol, 2011, 22(5): 335-342.
[13] MANTOVANI A, SICA A, SOZZANI S, et al. The chemokine system in diverse forms of macrophage activation and polarization [J]. Trends Immunol, 2004, 25(12): 677-686.
[14] CHINETTI-GBAGUIDI G, COLIN S, STAELS B. Macrophage subsets in atherosclerosis [J]. Nat Rev Cardiol, 2015, 12(1): 10-17.
[15] AMENGUAL J, BARRETT T J. Monocytes and macrophages in atherogenesis [J]. Curr Opin Lipidol, 2019, 30(5): 401-408.
[16] BOYLE J J, HARRINGTON H A, PIPER E, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype [J]. Am J Pathol, 2009, 174(3): 1097-1108.
[17] TABAS I. Macrophage death and defective inflammation resolution in atherosclerosis [J]. Nat Rev Immunol, 2010, 10(1): 36-46.
[18] FEIG J E, VENGRENYUK Y, REISER V, et al. Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome [J]. PLoS One, 2012, 7(6): e39790.
[19] RAHMAN K, VENGRENYUK Y, RAMSEY S A, et al. Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression [J]. J Clin Invest, 2017, 127(8): 2904-2915.
[20] LI J, LEI H T, CAO L, et al. Crocin alleviates coronary atherosclerosis via inhibiting lipid synthesis and inducing M2 macrophage polarization [J]. Int Immunopharmacol, 2018, 55: 120-127.
[21] MOMTAZI-BOROJENI A A, ABDOLLAHI E, NIKFAR B, et al. Curcumin as a potential modulator of M1 and M2 macrophages: new insights in atherosclerosis therapy [J]. Heart Fail Rev, 2019, 24(3): 399-409.
[22] ZHANG X, LIU M H, QIAO L, et al. Ginsenoside Rb1 enhances atherosclerotic plaque stability by skewing macrophages to the M2 phenotype [J]. J Cell Mol Med, 2018, 22(1): 409-416.
[23] BRENNER C, FRANZ W M, KüHLENTHAL S, et al. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages [J]. Int J Cardiol, 2015, 199: 163-169.
[24] BRUEN R, CURLEY S, KAJANI S, et al. Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis [J]. Cardiovasc Diabetol, 2017, 16(1): 143.
[25] HAVERSLAG R, PASTERKAMP G, HOEFER I E. Targeting adhesion molecules in cardiovascular disorders [J]. Cardiovasc Hematol Disord Drug Targets, 2008, 8(4): 252-260.
[26] TIWARI R L, SINGH V, BARTHWAL M K. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis [J]. Med Res Rev, 2008, 28(4): 483-544.
[27] WANG Y, WANG G Z, RABINOVITCH P S, et al. Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages [J]. Circ Res, 2014, 114(3): 421-433.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	GU Chonghuai, XIANG Xuejun, ZHENG Yuanxi, QIAO Rui, LIN Song. Efficacy of dapagliflozin in elderly patients undergoing coronary intervention with type 2 diabetes mellitus and ejection fraction reduced heart failure [J]. Practical Geriatrics, 2024, 38(10): 1025-1029.
[2]	XU Shouyong, YUAN Yong. Study on feasibility of dual-low-dose CT coronary angiography in elderly patients [J]. Practical Geriatrics, 2024, 38(10): 1054-1058.
[3]	ZHA Zhimin, LIU Huan, WANG Xiangming, LI Qiushuang, GUO Yan. Effect of cardiac valve calcification on prognosis of elderly patients with coronary heart disease [J]. Practical Geriatrics, 2024, 38(3): 245-250.
[4]	. [J]. Practical Geriatrics, 2024, 38(3): 308-311.
[5]	ZHANG Ying, XIE Ling, YE Jiaqi, QIANG Wenhui, YAN Xiaoyun, JIANG Ying, ZHANG Qing. Correlation between laminin and major adverse cardiovascular events in elderly patients with acute myocardial infarction [J]. Practical Geriatrics, 2024, 38(2): 149-151.
[6]	YANG Xue, NING Chun, ZHAO Juan, HAO Jing-bo, YANG Rong-li. Diagnostic value of growth differentiation factor 15 and cytokines in elderly patients with coronary heart disease complicated with frailty [J]. Practical Geriatrics, 2023, 37(10): 1009-1013.
[7]	ZHENG Ya-guo, XU Tian, ZUO Guang-feng, CHEN Liang, LIN Song. Effect of drug-coated balloons in patients with Medina 0,0,1 coronary bifurcation lesion [J]. Practical Geriatrics, 2023, 37(6): 599-602.
[8]	SONG Chun-mei, YIN Ya-juan, LIU Yong-sheng, GUO Qi-feng, CHEN Jie, WEI Mei. Predictive value of anxiety on adverse cardiovascular events in elderly patients after percutaneous coronary intervention [J]. Practical Geriatrics, 2023, 37(4): 352-355.
[9]	. [J]. Practical Geriatrics, 2023, 37(4): 395-397.
[10]	JIANG Lei, JIA Zhi-qiang, YU Jian, LI Xiao-qing, ZHANG Dong-mei, HUANG Jing-jing. Effects of intensive rosuvastatin treatment on the inflamm-aging related indexes and clinical efficacy in elderly patients with acute coronary syndrome receiving percutaneacs coronary intervention [J]. Practical Geriatrics, 2023, 37(3): 265-269.
[11]	. [J]. Practical Geriatrics, 2023, 37(2): 109-111.
[12]	JI Jia-lin, LIU Jing, WANG Xue-li, FENG Hong-lin, HAN Xu. Ameta-analysis and sequential analysis of the effects of Guanxinping on coronary heart disease [J]. Practical Geriatrics, 2023, 37(2): 128-133.
[13]	WEI Mei, GUO Qi-feng, DUAN Li-nan, YIN Ya-juan, LIU Gang, ZHENG Ming-qi, LIU Yong-sheng. Association between subclinical hypothyroidism and death in elderly patients after percutaneous coronary intervention [J]. Practical Geriatrics, 2023, 37(2): 138-141.
[14]	YAO Jun-xiu, GUO Jin-chun, HAO Xiao-dan, LI Long-xin, YANG Xue, WANG Zhang. Expression and diagnostic value of hepatocyte growth factor in patients with chronic coronary syndrome [J]. Practical Geriatrics, 2023, 37(2): 173-177.
[15]	. [J]. Practical Geriatrics, 2023, 37(2): 191-194.